Related Experiment Video

Updated: May 31, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm

Don L Gibbons1, Sabrina Pricl, Hagop Kantarjian

  • 1Department of Thoracic, Head/Neck Medical Oncology and Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Cancer
|July 7, 2011
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) are crucial cancer treatments, but resistance often arises from gatekeeper mutations. New TKIs are being developed using structural biology to overcome these resistant mutations in oncogenic kinases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Tyrosine kinase inhibitors (TKIs) are a cornerstone of modern cancer therapy.
  • Imatinib mesylate, a BCR-ABL1 inhibitor, pioneered TKI development for various cancers.
  • TKI therapy faces a significant challenge in the development of drug resistance.

Discussion:

  • Acquired mutations, particularly at gatekeeper residues, are a primary mechanism of TKI resistance.
  • The threonine-to-isoleucine mutation at codon 315 in BCR-ABL1 exemplifies highly resistant mutations.
  • These gatekeeper mutations confer resistance to existing TKIs, limiting treatment efficacy.

Key Insights:

  • Structural biology advances enable the rational design of novel TKIs.
  • New TKIs are being developed to specifically target and inhibit kinases with gatekeeper mutations.
  • This targeted approach aims to restore therapeutic efficacy against resistant cancers.

Outlook:

  • Further research into kinase structural biology will drive the development of next-generation TKIs.
  • Overcoming TKI resistance through rational drug design holds promise for improved cancer patient outcomes.
  • The development of TKIs active against gatekeeper mutations represents a significant step forward in personalized cancer medicine.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...